Compare
Innospec Inc. vs Ingevity Corp vs Balchem Corp vs FMC Corp
| Latest fiscal year | Innospec Inc. IOSP | Ingevity Corp NGVT | Balchem Corp BCPC | FMC Corp FMC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.78B | $1.17B | $1.04B | $3.47B |
| Revenue growth (YoY) | -3.7% | -2.7% | +8.8% | -18.3% |
| Gross margin | 27.7% | 39.5% | 35.7% | 37.0% |
| Operating margin | 7.3% | 35.9% | 20.2% | -47.0% |
| Net margin | 6.6% | -14.3% | 14.9% | -64.6% |
| Net income | $116.60M | -$167.10M | $154.84M | -$2.24B |
| EPS (Diluted) | $4.67 | -$4.61 | $4.75 | -$17.88 |
| Operating cash flow | $138.30M | $331.20M | $216.56M | -$6.20M |
| Free cash flow | n/a | $273.50M | n/a | -$102.50M |
| Cash & equivalents | $292.50M | $78.10M | $74.57M | $584.50M |
| Total assets | $1.83B | $1.65B | $1.69B | $9.69B |
| Total liabilities | $499.50M | $1.62B | $428.84M | n/a |
| Shareholders' equity | $1.33B | $29.70M | $1.26B | $2.10B |
| Return on year-end equity | 8.8% | -562.6% | 12.3% | -106.7% |
| Shares outstanding | n/a | 35.49M | 32.06M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Innospec Inc. | Ingevity Corp | Balchem Corp | FMC Corp |
|---|---|---|---|---|
| Latest | $1.78B Ended 2025-12-31 | $1.17B Ended 2025-12-31 | $1.04B Ended 2025-12-31 | $3.47B Ended 2025-12-31 |
| 1 year earlier | $1.85B Ended 2024-12-31 | $1.20B Ended 2024-12-31 | $953.68M Ended 2024-12-31 | $4.25B Ended 2024-12-31 |
| 2 years earlier | $1.95B Ended 2023-12-31 | $1.22B Ended 2023-12-31 | $922.44M Ended 2023-12-31 | $4.49B Ended 2023-12-31 |
| 3 years earlier | $1.96B Ended 2022-12-31 | $1.67B Ended 2022-12-31 | $942.36M Ended 2022-12-31 | $5.80B Ended 2022-12-31 |
| 4 years earlier | $1.48B Ended 2021-12-31 | $1.39B Ended 2021-12-31 | $799.02M Ended 2021-12-31 | $5.05B Ended 2021-12-31 |